Poloxamer-188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute myocardial infarction

American Journal of Cardiology

Volumn 78, Issue 7, 1996, Pages 747-750

  O'Keefe Jr , James H ^a   Grines, Cindy L ^a   DeWood, Marcus A ^a   Schaer, Gary L ^a   Browne, Kevin ^a   Magorien, Raymond D ^a   Kalbfleisch, John M ^a   Fletcher Jr , William O ^a   Bateman, Timothy M ^a   Gibbons, Raymond J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; POLOXAMER; SURFACTANT;

AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CREATININE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PILOT PROJECTS; POLOXALENE; PROSPECTIVE STUDIES; SURFACE-ACTIVE AGENTS; TREATMENT OUTCOME;

EID: 10644250940     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00414-6     Document Type: Article

References (15)

1. Hunter RL, Papadea C, Gallagher CJ, Finlayson DC, Check IJ. Increased blood viscosity during coronary artery bypass surgery: studies to evaluate the effects of soluble fibrin and poloxamer-188. Thromb Haemostasis 1990;63:6-12.
2. Carter C, Fisher TC, Hamai H, Johnson CS, Meiselman JH, Nash GB, Stuart J. Haemorheological effects of a nonionic copolymer surfactant (poloxamer-188). Clin Hemorheol 1992;12:109-120.
3. Hunter RL, Bennett B, Cheek JJ. The effect of poloxamer 188 on the rate of in vitro thrombolysis mediated by t-PA and streptokinase. Fibrinolysis 1990;4:117-123.
4. Carr ME, Jr., Powers PL, Jones MR. Effects of poloxamer 188 on the assembly, structure, and dissolution of fibrin clots Thrombosis Haemostasis 1991;66:565-568.
5. Schaer GL, Hursey TL, Abrahams SL, Buddemeier K, Ennis B, Rodriguez ER, Hubbell JP, Moy J, Parrillo JE. Reduction in reperfusion-induced myocardial necrosis in dogs by RheothRx injection (poloxamer-188, N.F.), a hemorheological agent that alters neutrophil function. Circulation 1994;90:2964-2975.
6. Robinson KA, Hunter RL, Stack JE, Hearn JA, Apkarian RP, Roubin GS. Inhibition of coronary arterial thrombosis in swine by infusion of poloxamer 188. J Invas Cardiol 1990;2:9-20.
7. Schaer GL, Spaccavento LJ, Browne KF, Krueger KA, Krichbaum D, Phelan JM, Fletcher WO, Grines CL, Edwards S, Jolly MK, Gibbons RJ. Beneficial effects of RheothRx (poloxamer 188, N.F.) injection in patients receiving thrombolytic therapy for acute myocardial infarction. Circulation 1996 (in press).
8. Weaver WD. Randomized, placebo controlled trial of RheothRx (poloxamer 188) injection in patients with suspected acute myocardial infarction (abstr). Circulation 1995;92(8):I-24.
9. Gibbons RJ, Christian TF, Hopfenspirger M, Hodge DO, Bailey KR. Myocardium at risk and infarct size after thrombolytic therapy for acute myocardial infarction; implications for the design of randomized trials of acute intervention. J Am Coll Cardiol 1994;24:616-623.
10. O'Connor MK, Gibbons RJ, July JE, O'Keefe JH, Jr., Ali A. Quantitative myocardial SPECT for infarct sizing; feasibility of a multicenter trial evaluated using a cardiac phantom. J Nucl Med 1995;36:1130-1136.
11. MacLeod CM, McKenna R, Emanuele RM. Clinical pharmacology of poloxamer 188 in healthy subjects (abstr). Clin Pharmacol Ther 1993;53:211.
12. Jewell RC, Kisor DF, Krueger KA, Wargin WA. Pharmacokinetics of RheothRx injection in healthy male volunteers (abstr). Pharm Res 1994;11:3-336.
13. Weaver WD. Randomized, placebo control led trial of RheothRx (poloxamer 188) injection in patients with suspected acute myocardial infarction (AMI) (abstr). Circulation 1995;92(8):I-24.
14. Laster SB, O'Keefe JH, Gibbons RJ. Incidence and importance of thrombolysis in myocardial infarction grade 3 flow after primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996:78:617-620.
15. O'Keefe JH, Grines CL, DeWood MA, Bateman TM, Christian TF, Gibbons RJ. Factors influencing myocardial salvage with primary angioplasty. J Nucl Cardiol 1995;2:35-41.